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Abstract The role of nucleotides in intracellular energy
provision and nucleic acid synthesis has been known for
a long time. In the past decade, evidence has been
presented that, in addition to these functions, nucleo-
tides are also autocrine and paracrine messenger
molecules that initiate and regulate a large number of
biological processes. The actions of extracellular nucle-
otides are mediated by ionotropic P2X and metabo-
tropic P2Y receptors, while hydrolysis by ecto-enzymes
modulates the initial signal. An increasing number of
studies have been performed to obtain information on
the signal transduction pathways activated by nucleo-
tide receptors. The development of specific and stable
purinergic receptor agonists and antagonists with ther-
apeutical potential largely contributed to the identifi-
cation of receptors responsible for nucleotide-activated
pathways. This article reviews the signal transduction
pathways activated by P2Y receptors, the involved
second messenger systems, GTPases and protein
kinases, as well as recent findings concerning P2Y
receptor signalling in C6 glioma cells. Besides vertical
signal transduction, lateral cross-talks with pathways
activated by other G protein-coupled receptors and
growth factor receptors are discussed.
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Abbreviations
AC adenylate cyclase
Ap3AP
1,P
3-di(adenosine-50)triphosphate
Ap4AP
1,P
4-di(adenosine-50)tetraphosphate
AR adrenergic receptor
COX cyclooxygenase
DAG diacylglycerol
ERK extracellular signal-regulated kinase
GFAP glial fibrillary acidic protein
GPCR G protein-coupled receptor
HT hydroxytryptamine
IP3 inositol (1,4,5)-triphosphate
PAP adenosine-30,50-biphosphate
PI phosphatidylinositol
PL phospholipase
PI 3-K phosphatidylinositol 3-kinase
PPADS pyridoxalphosphate-6-azophenyl-20,
40-disulphonate
Pyk2 proline-rich tyrosine kinase 2
RKIP Raf kinase inhibitory protein
RTK receptor tyrosine kinase
Introduction
Pharmacological properties of P2Y receptors
Extracellular actions of adenine nucleotides were ini-
tially characterised in the cardiovascular system by
Drury and Szent-Gyorgyi [1]. It took more than four
decades before the concept of purinergic signalling was
accepted, but now it is well established that nucleo-
tides initiate and regulate a variety of biological
processes, including neurotransmission, inflammation,
regulation of blood pressure, platelet aggregation, cell
growth and differentiation (Abbracchio et al. [2];
Burnstock and Williams [3]; Burnstock [4]; Ralevic
and Burnstock [5]).
Purinergic Signalling (2006) 2:451–469
DOI 10.1007/s11302-006-9008-0
K. Van Kolen:H. Slegers (*)
Department of Biomedical Sciences, Cellular Biochemistry,
University of Antwerp,
Universiteitsplein 1,
2610 Wilrijk-Antwerpen, Belgium
e-mail: herman.slegers@ua.ac.be
K. Van Kolen
CNS research, Johnson & Johnson, PRD,
Janssen Pharmaceutica,
Beerse, BelgiumNucleotides are released in the extracellular fluid by
cell lysis, exocytosis, secretion of granules, efflux and
upon cellular stress such as changes in osmolarity and
mechanical perturbations. Once released, they mediate
their effect by stimulation of nucleotide receptors.
Based on pharmacological properties, the first sug-
gestion for the existence of ionotropic P2X receptors
and metabotropic P2Y receptors was made by
Burnstock and Kennedy [6]. After cloning, multiple
subtypes of P2X and P2Y receptors were characterised
unambiguously (Abbracchio and Burnstock [7]
Burnstock and Williams [3]; Fredholm et al. [8]).
Up to now, the P2Y receptor family comprises at least
eight subtypes, P2Y1,P 2 Y 2,P 2 Y 4,P 2 Y 6,P 2 Y 11,P 2 Y 12,
P2Y13 and the recently identified P2Y14 receptor
(Ralevic and Burnstock, [5] Abbracchio et al. [9];
Communi et al. [10]; Hollopeter et al. [11]; Zhang
et al. [12]). According to the agonist profile, P2Y
receptors can be subdivided into receptors responding
to adenine mono- and dinucleotides (P2Y1, P2Y11,
P2Y12,P 2 Y 13), and to uridine nucleotides (P2Y4,
P2Y6), and receptors for adenine and uridine nucleo-
tides (P2Y2). The pharmacological profile of the
recently cloned P2Y14 receptor is distinct from the
other P2Y receptors since UDP-glucose, UDP-galac-
tose, UDP-glucuronic acid and UDP-N-acetylglucos-
amine are specific ligands of this receptor (Chambers
et al. [13]). Natural P2Y receptor ligands do not
exclusively bind to one receptor subtype. ADP is an
agonist of P2Y1,P 2 Y 12 and P2Y13 receptors, whereas
ATP is a full agonist of P2Y2 and P2Y11,b u tap a r t i a l
agonist or antagonist of P2Y1,P 2 Y 12 and P2Y13
receptors. Although the pharmacological properties of
P2Y receptors (Table 1) are well conserved between
species, some remarkable differences have been ob-
served. While UTP acts as an agonist of both human and
rat P2Y4 receptors, ATP is a potent agonist of the rat
P2Y4, but an antagonist of the human orthologue.
Mutational analysis revealed that the second extracel-
lular loop of the P2Y4 receptor is responsible for the
opposing effect of ATP in both species (Herold et al.
[14]). A similar phenomenon is observed when human
and canine P2Y11 receptors were stably expressed in
CHO-K1 and 1321N1 astrocytoma cells. Whereas the
Table 1 Pharmacological profile of P2Y receptors and second messenger systems.
Agonists Antagonists Effector G protein
P2Y1 2MeSADP, ADP, ADP"S,
Ap3A, MRS2365
Suramin, PPADS, PAP, MRS2179, MRS2216,
MRS2279, MRS2500, MRS 2603
PLC, IK, Ca Gq/G11/12
P2Y2 UTP+S, ATP+S, UTP, ATP,
INS37217, Ap4A
Suramin PLC, IK, Ca Gi/Gq
P2Y4 UTP+S, UTP, ATP
a ATP
a, PPADS PLC, IK Gq/G11/12
P2Y6 UDP"S, UDP, UTP, INS48823 PPADS, suramin, MRS2567 PLC, IK Gq/G11/12
P2Y11 ATP!S, ATP+S, ATP Suramin AC, PLC Gq/Gs
P2Y12 2MeSADP, ADP, Ap3A, ATP,
Ap4A
AR-C69931MX, AR-C67085, AR-C78511KF,
clopidogrel, 2MeSAMP, DIDS, suramin, MRS2395
AC, IK, Ca Gi/o
P2Y13 2MeSADP, ADP, Ap3A, ATP AR-C69931MX, Ap4A, PPADS, suramin, MRS2211,
MRS2603
AC, PLC, ICa Gi/Gq
P2Y14 UDP-glucose, UDP-galactose,
UDP-glucuronic acid,
UDP-N-acetylglucosamine
AC, ICa Gi
a ATP acts as an agonist of the rat P2Y4 but as an antagonist of
thehumanP2Y4 receptor (Herold et al [14]). Reactive blue 2 is not
included in the list since it displays lack of specificity towards the
different P2Y subtypes. References: Abbracchio et al. [9]; Com-
muni et al. [10, 191]; Chambers et al. [13]; Claes and Slegers [17];
Kim et al. [26]; Xu et al. [27]; Boyer et al. [38, 189, 190]; Grobben
et al. [40]; Marteau et al. [47]; Filippov et al. [57–60, 63]; Simon
et al. [61]; Wirkner et al. [62]; Korcok et al. [192]; Muller [193];
Skelton et al. [194]; Yerxa et al. [195]; Jacobson et al. [196]; von
Ku ¨ gelgen [197]. Abbreviations: Ap3A, P
1,P
3-di(adenosine-50)
triphosphate; Ap4A, P
1,P
4-di(adenosine-50)tetraphosphate; AR-
C69931MX, N
6-(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)
-",+-dichloromethylene ATP; AR-C67085, 2-propylthio-D-"+-
dichloromethylene adenosine 50-triphosphate; AR-C78511KF,
(E)-N-[1-[7-(hexylamino)-5-(propylthio)-3H-1,2,3-triazolo-[4,5-d]-pyri-
midin-3-yl]-1,5,6-trideoxy-"-D-ribo-hept-5-enofuranuronoyl]-L-aspartic
acid monoammonium salt; DIDS, 4,40-diisothiocyanatostilbene-2,
20-disulphonic acid; INS37217 [P(1)-(uridine 50)-P (4)-(20-deoxy-
cytidine 50)tetraphosphate tetrasodium salt; INS48823 P
1-((2-benzyl-1,
3-dioxolo-4-yl)uridine 50)P
3-(uridine 50) triphosphate; MRS2179, N
6-
methyl-20-deoxyadenosine-30,50-bisphosphate; MRS2211, pyridoxal- 50-
phosphate-6-azo-(2-chloro-5-nitrophenyl)-2,4-disulphonate; MRS2216,
20-deoxy-2-chloro-N
6-methyladenosine-30,50-bisphosphate; MRS2279,
2-chloro-N
6-methyl-(N)-methanocarba-20-deoxyadenosine 30,50-bis-
phosphate; MRS2365, [(10S,20R,30S,40R,50S)-4-[(6-amino-2-methylthio-
9H-purin-9-yl)-1-diphosphoryloxymethyl]bicyclo[3.1.0]hexane-2, 3-diol];
MRS2395, 2-dimethyl-propionic acid-3-(2-chloro-6-methylaminopurin-
9-yl)-2-(2,2-dimethylpropionyloxy-methyl)-propylester; MRS2500, 2-io-
do-N
6-methyl-(N)-methanocarba-20-deoxyadenosine 30,50-bisphosphate;
MRS2567, 1,2-di-(4-isothiocyanatophenyl)ethane; MRS2603, pyridox-
al-50-phosphate-6-azo-(4-chloro-3-nitrophenyl)-2,4-disulphonate;
PPADS, pyridoxalphosphate-6-azophenyl-20,40-disulfonic acid.
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phosphate nucleotides, the canine orthologue displayed
more selectivity towards the corresponding diphos-
phates. In this case, the nucleotide selectivity is due to
differences in the amino acid sequence at the juxtapo-
sition of TM6 and the third extracellular loop also
reported to play an important role in agonist selectivity
and signalling of other G protein-coupled receptors
(GPCR) (Qi et al. [15]; Lawson and Wheatley [16]).
Despite their chemical stability, extracellular nu-
cleotides are metabolised by several ecto-enzymes
(Claes and Slegers [17]; Czajkowski and Baranska
[18]; Goding et al. [19]; Zimmerman [20]). Extracellu-
lar hydrolysis complicates the evaluation of nucleo-
tide-mediated effects on different cell types and can be
overcome by the use of specific non-hydrolysable
receptor agonists or ecto-enzyme inhibitors. Some
P2Y receptor antagonists, such as pyridoxalphosphate-
6-azophenyl-20,40-disulfonic acid (PPADS), suramin,
reactive blue 2 and 4,40-diisothiocyanatostilbene-2,20-
disulphonic acid (DIDS), are inhibitors of nucleotide
hydrolyzing enzymes and are often used in studies of
nucleotide-mediated signalling (Grobben et al. [21]).
Nevertheless, care must be taken for the interpretation
of experimental data since it is also shown that cells can
internalise some of these molecules (Claes et al., [22]).
Therefore specific P2Y receptor antagonists, devel-
oped for therapeutical purposes, have to be used to
overcome the lack of specificity (Boeynaems et al.
[23]; Lambrecht et al. [24]; Kam and Nethery [25]; Kim
et al. [26]; Xu et al. [27]).
P2Y receptor expression on rat C6 glioma cells
Rat C6 glioma is a tumoral cell line of glial origin with
oligodendrocytic, astrocytic and neuronal progenitor
properties. Due to a point mutation in Fphosphatase
and tensin homologue deleted on chromosome ten_
(PTEN), the phosphatidylinositol 3-kinase (PI 3-K)/
PKB signalling pathway is constitutively active and
contributes to the proliferative and invasive properties
of these cells (Kubiatowski et al. [28]; Roymans and
Slegers [29]; Grobben et al. [30]). In addition, cell
proliferation is sustained by secreted growth factors
that stimulate growth factor receptors present on these
cells. Such autocrine mechanisms are reported for
IGFR, bFGFR and PDGFR (Okumura et al. [31];
Resnicoff et al. [32]; Strawn et al. [33]).
In C6 cells, an increase in cAMP by stimulation of
the "-adrenergic receptor ("-AR) or by addition of
membrane permeable cAMP analogues, e.g., dibutyryl
cAMP (dBcAMP) or 8-chloro-cAMP, induces differ-
entiation into an astrocyte type II (Roymans et al.
[34]). During this process, cessation of cell growth is
accompanied by a shift in intermediate filament
synthesis from vimentin to glial fibrillary acidic protein
(GFAP) (Backhovens et al. [35]). The latter protein is
an astrocytic differentiation marker whose expression
is regulated by cAMP at the transcriptional and
translational level (Messens and Slegers [36]).
In our laboratory, the signalling pathways activated by
extracellular nucleotides, and in particular those affecting
cell proliferation and differentiation of C6 cells, were
studied in detail. The presence of a P2Y receptor on these
cells that negatively affects adenylate cyclase (AC) was
postulated for more than a decade (Pianet et al. [37]; Boyer
et al. [38]). This receptor is coupled to a Gi protein and
has been denominated P2YAC- (Claes et al. [39]; Grobben
et al. [40]) before its identification as the P2Y12 receptor
initially cloned from blood platelets (Czajkowski et al.
[41]; Hollopeter et al. [11]; Jin et al. [42]). C6 cells also
express the phospholipase (PL)C"-coupled P2Y1,P 2 Y 2,
P2Y4 and P2Y6 receptors (Czajkowski et al. [41]; Nicholas
et al. [43]; Tu et al. [44]; Claes and Slegers [17]). Recently,
we also demonstrated the presence of P2Y13 mRNA (Van
Kolen and Slegers [45]) implicating the expression of
three ADP-activated receptors in these cells, i.e., P2Y1,
P2Y12 and P2Y13. Although 2MeSADP is reported as a
potent P2Y1,P 2 Y 12 and P2Y13 agonist, stimulation with
this compound inhibits AC, but induces no significant
activation of PLC, indicating that the P2Y1 receptor is not
activated by ADP in cells grown in chemically defined
medium (Grobben et al. [40]). This is confirmed by
Czajkowski et al. [46], who showed that, in cells cultivated
in the presence of fetal calf serum, ADP signalling is
predominantly determined by the P2Y1 receptor. Howev-
er, upon serum deprivation, expression of the P2Y1
receptor is decreased and the P2Y12 receptor becomes
the main activated receptor. Characterization of P2Y13
receptor function is complicated by the fact that P2Y12
and P2Y13 receptors have almost the same agonist profile
(Table 1). The receptor antagonist N
6-(2-methyl-
thioethyl)-2-(3,3,3-trifluoropropylthio)-",+-dichloromethy-
lene ATP (AR-C69931MX), often used as a specific
P2Y12 antagonist, also blocks the P2Y13 receptor (Marteau
et al. [47]). While the human and mouse P2Y13 receptor,
like the P2Y12, is more potently activated by 2MeSADP
than ADP, the rat P2Y13 receptor shows a higher
selectivity for ADP (Fumagalli et al. [48]). In C6 cells,
further distinction between the signalling of P2Y12 and
P2Y13 receptors can be made by the use of PPADS, a
P2Y13 antagonist without effect on P2Y12,a n dP
1,P
4-
di(adenosine-50) tetraphosphate (Ap4A), a P2Y13 antago-
nist that stimulates the P2Y12 receptor (Claes et al. [39];
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recently synthesised PPADS derivatives pyridoxal-50-
phosphate-6-azo-(2-chloro-5-nitrophenyl)-2,4-disulphonate
(MRS2211) and pyridoxal-50-phosphate-6-azo-(4-chloro-3-
nitrophenyl)-2,4-disulphonate (MRS2603) have no effect
on the P2Y12 receptor but antagonise the P2Y13 receptor
(Kim et al. [26]).
Although P2Y receptor expression in C6 cells de-
pends on the cultivation conditions (Czajkowski et al.
[46]), unpublished data of our laboratory revealed that
induction of differentiation into astrocytes type II by
dbcAMP (1 mM)- or (-)-isoproterenol (5 2M) does not
significantly alter the expression of P2Y receptors.
These observations are in accordance with previous
studies on the expression of P2Y1, P2Y2, P2Y4, P2Y6,
P2Y12,P 2 Y 13 and P2Y14 receptors in glial cells and
primary astrocytes (Bianco et al. [49]; Fumagalli et al.
[48, 50];Sasaki etal.[51]).ThefunctionofP2Yreceptor
expression in glial cells is still under investigation, but a
number of studies point to an important role in the
intercellular communication between astrocytes and
neurons (Bezzi and Volterra, [52]). Another well
documented effect of extracellular ATP is induction
of reactive astrogliosis upon activation of ERK and
cyclooxygenase (COX)-2 (Brambilla et al. [53]).
Similar to the observations made in C6 cells,
functional responses of P2Y receptor subtypes in
microglial cells depend on cultivation conditions. In
N9 mouse brain microglia stimulation of expressed P2Y
receptors induces Ca
2+ mobilization but only P2Y6 and
P2Y14 receptor-mediated responses are increased upon
activation of microglia with lipopolysaccharide. The
enhanced P2Y6 response is correlated with mRNA
increase which was not the case for the P2Y14
receptor-mediated Ca
2+ mobilization (Bianco et al.
[49]). Furthermore, stimulation of microglial P2Y12/13
receptors induces membrane ruffling and chemotaxis
towards injured neurons through Gi/o protein-medi-
ated activation of Rac (Honda et al. [54]). The
observations made in astrocytes and microglial cells
emphasise the importance of P2Y receptors in brain
signalling and identify these receptors as putative
targets in defective neurotransmission, neuroimmune
functioning, cell survival and cell proliferation in
response to oxidative stress and brain injury.
P2Y receptor-activated signalling cascades
Second messengers
P2Y receptors are generally linked to PLC activation
that catalyses the rapid hydrolysis of phosphatidylino-
sitol 4,5-bisphosphate into the intracellular messenger
inositol 1,4,5-triphosphate (IP3) and diacylglycerol
(DAG). Activation of PLC occurs by Gi!- and/or
Gq!-dependent mechanisms (Communi et al. [55]).
Besides signalling through G! subunits, intracellular
Ca
2+ concentration is also affected by G"+ subunit-
dependent interaction with voltage-gated Ca
2+ chan-
nels. Several reports indicated modulation of K
+
currents and PLC" activation induced by distinct
domains of G"+ (Mirshahi et al. [56]). Co-expression
studies performed in rat sympathetic neurons demon-
strated that P2Y1, P2Y2 and P2Y6 receptors trigger the
closing of N-type Ca
2+ and M-type K
+ channels,
whereas P2Y4 receptor stimulation also displayed
coupling to M-type K
+ channels producing a less
efficient inhibition of Ca
2+ currents. In rat brain cap-
illary endothelial cells, it was shown that the P2Y12
receptor inhibits ICa(N) and activates a G protein-
coupled inward rectifier K
+ (GIRK) channel. Interest-
ingly, stimulation of the P2Y1 receptor also induces a
K
+ current that is rapidly followed by inactivation.
Inhibition of ICa(N) by P2Y12 receptor stimulation is
also reported in PC12 cells while in HEK 293 this
inhibition is mediated by the P2Y13 receptor (Filippov
et al. [57–60]; Simon et al. [61]; Wirkner et al. [62]).
From co-expression studies of P2Y receptors with
GIRK1 or GIRK2 in rat sympathetic neurons, it was
concluded that P2Y receptors activate GIRK channels
by the "+ subunits of Gi/o and inhibit these channels by
the ! subunits of Gq (Filippov et al. [63]).
P2Y-induced calcium release is followed by opening
of voltage-independent Ca
2+ channels. Although this
response is observed in a variety of cell types, the
physiological implications are miscellaneous. In this
context, it has been reported that extracellular ATP
induces a Ca
2+ wave that propagates through neigh-
bouring astrocytes by GAP junctions (Suadicani et al.
[64]). In situations of increased neuronal activity or cell
damage, ATP stimulates a Ca
2+-dependent proton-
efflux from astrocytes. Acidification of the extracellular
environment serves as a negative feedback mechanism
for neurotransmitter release, but also increases blood
flow by vasodilatation in cerebral arterioles (Dienel and
Hertz [65]; Dixon et al. [66]). Although Ca
2+ signalling
is observed in a variety of cell types, the time
dependence of the response is cell type specific. This
is especially the case for the P2Y1 receptor which
triggers persistent or transient Ca
2+ responses when it is
expressed in human 1321N1 astrocytoma or C6 glioma
cells, respectively (Czajkowski et al. [41]; Sellers et al.
[67]). A recent study also revealed that, in glial cells,
prolongation of the P2Y1 receptor-induced Ca
2+ re-
sponse is regulated by interaction with the Na
+/H
+
454 Purinergic Signalling (2006) 2:451–469exchanger regulatory factor type-2 which determines
the signalling pathways that are ultimately activated in
different cell types (Fam et al. [68]). Indeed, while
transient P2Y1 receptor signalling increases prolifera-
tion in C6 cells, sustained signalling triggers apoptotic
cascades in 1321N1 astrocytoma cells (Czajkowski et al.
[46]; Sellers et al. [67]).
A well-known response to PLC-generated DAG and
IP3/Ca
2+ is the activation of classical PKCs that are
involved in rapid internalisation and desensitisation of
GPCRs through phosphorylation of residues localised
in their cytoplasmic tail. In this regard, PKC"Ii s
reported to attenuate phosphatidylinositol (PI)-hydro-
lysis induced by P2Y1 and P2Y2 receptors in endothelial
cells (Chen and Lin [69]). In astrocytes, high frequency
stimulation of the P2Y1 receptor by repeated addition
of ATP causes rapid suppression of the P2Y1 receptor-
induced Ca
2+ response. This phenomenon, observed as
Ca
2+ oscillations, is mediated by protein kinase C-
dependent phosphorylation of Thr339 in the carboxy-
terminus of the P2Y1 receptor (Fam et al. [70]). Besides
modulation of receptor responsiveness, PKC signalling
also affects long term effects. In the human osteoblastic
HOBIT cell line, ATP increases expression of the early
growth response protein-1 by a mechanism that requires
aC a
2+-independent PKC isoform (Pines et al. [71]). In
vascular smooth muscle cells, UDP stimulates cell cycle
progression by a PLC- and PKC%-dependent cascade
(Hou et al. [72]). The same isoform is involved in ATP-
mediated mitogenic signalling in astrocytes, but in these
cells PKC% activation does not involve PLC but
requires PLD-dependent choline formation (Neary
et al. [73]).
In addition to PLC-coupled receptors, a growing
number of P2Y receptors have been shown to affect the
activity of AC. Besides the existence of indirect
mechanisms linked to an increase in cAMP (discussed
in Communi et al. [55]), only the P2Y11 receptor is
directly coupled to activation of AC and PLC while
P2Y12, P2Y13 and P2Y14 receptors negatively affect
cAMP synthesis (Chambers et al. [13]; Communi et al.
[10]; Hollopeter et al. [11]; Zhang et al. [12]).
Adenylate cyclase-dependent signalling is often me-
diated by the cAMP-regulated kinase PKA. Stimula-
tion of the P2Y11 receptor with ATP is shown to
activate human monocyte-derived dendritic cells by
increased cAMP/PKA signalling (Wilkin et al. [74]). In
bovine adrenocortical fasciculate cells, ADP and ATP
increase cortisol production through PKA activation
by an as yet unidentified Gs protein-coupled P2Y
receptor (Nishi et al. [75]). Although in unstimulated
cells the cytosolic cAMP concentration is already
low, its further decrease by Gi protein-coupled re-
ceptors is sometimes sufficient to exert a significant
inhibitory action towards PKA. Such a response is
reported in microglial cells where ATP and ADP
binding to P2Y12/13 receptors mediate chemotaxis by
PKA-dependent translocation of "1 integrins to ruf-
fling regions of the cell (Nasu-Tada et al. [76]).
Despite the fact that cells express a myriad of
different GPCRs and downstream acting regulators,
receptor stimulation promotes rapid and specific
responses. In addition, multiple GPCRs, sharing the
same second messenger cascade, can induce different
cellular events in one cell type indicating that GPCR
signal propagation requires physical interactions in a
defined cellular compartment. An example of spatial
organised signalling is the "-arrestin-dependent target-
ing of an activated receptor into clathrin-coated vesicles
or enrichment in membrane microdomains (lipid rafts)
formed by cholesterol and sphingolipids (Anderson
[77]; DeFea et al. [78]). Modulation of receptor
function by rafts is confirmed for an increasing number
of GPCRs including P2Y receptors (Anderson [77];
Ostrom and Insel [79]). In endothelial cells, it is
reported that P2Y receptor-induced vasodilatation is
abolished by disruption of caveolae with methyl-"-
cyclodextrin (Kaiser et al. [80]). In C6 glioma cells,
signalling by P2Y2 and 5-hydroxytryptamine (HT)2A
receptors is attenuated after knock-down of caveolin-1
by si-RNA. Moreover, interaction between the 5-HT2A
receptor and caveolin-1 facilitates its interaction with
G!q. Since P2Y2 receptor mRNA is downregulated by
caveolin-1 knock-down, further studies are required to
demonstrate localisation of P2Y2 receptors in caveolae
of C6 cells (Bhatnagar et al. [81]).
Small GTPases as molecular switches
The processing of extracellular stimuli by GPCRs
often involves signalling by second messengers
(cAMP, DAG, Ca
2+) towards small GTPases and/or
cross-talk with tyrosine kinases. Gq protein-coupled
receptor signalling via PLC" induces formation of
DAG and IP3,C a
2+ mobilisation and activation of
PKC ultimately leading to activation of proline-rich
tyrosine kinase 2 (Pyk2). Pyk2 cooperates with Src to
recruite Grb2 and SOS, a guanine nucleotide exchange
factor (GEF) that activates Ras (Lev et al. [82]). Such a
mechanism is reported for Ras-dependent ERK acti-
vation induced by the protease-activated receptor-1 in
astrocytes (Wang and Reiser [83]). In PC12 cells,
stimulation of the P2Y2 receptor also triggers tyrosine
phosphorylation of Pyk2, but further signalling to Ras
involves EGFR transactivation by Src (Soltoff et al.
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reported for Gi protein-coupled receptors, but this
proceeds through G"+ subunit-mediated activation of
PI 3-K+ and Shc (Ellis et al. [85]; Lopez-Ilasaca et al.
[86]).
GEFs can also be regulated in a tyrosine kinase-
independent manner that proceeds through direct
activation by cAMP, DAG and Ca
2+ or by interaction
with G! subunits as observed for the Gq/11 protein-
mediated activation of RhoA (Bhattacharya et al. [87];
Bos [88]; Lutz et al. [89]; Walker et al. [90]).
P2Y receptor signalling towards GTPases is involved
in short term responses, such as stress fibre formation or
modulation of cell adhesion, but also in long term
responses like cell proliferation. Mitogenic Ras-depen-
dent P2Y responses are reported for C6 and HEK293
cells where Ras is implicated in P2Y2 receptor-depen-
dent signalling to the ERK pathway (Gao et al. [91];
Tu et al. [44]). On the other hand, increased prolifer-
ation of C6 cells by the P2Y12 receptor proceeds
independently of Ras, but requires RhoA-dependent
activation of ERK and Rho-associated coiled-coil-
containing protein kinase (ROCK) (Grobben et al.
[40]; Van Kolen and Slegers, unpublished data).
Interestingly, when the P2Y12 receptor is expressed
in CHO cells it activates ERK and RhoA/ROCK
by independent mechanisms (Soulet et al. [92]).
Another example of cross-talk between P2Y recep-
tors and GTPases is observed in blood platelets. As
mentioned above, releaseof ADPandsubsequentP2Y1
and P2Y12 receptor binding is essential for collagen-
induced platelet aggregation. A crucial step for imme-
diate and sustained aggregation of platelets is the
activation of Rap1 that increases the affinity between
integrin !IIb"3 and fibrinogen. Knock-out studies
revealed that ADP-induced GTP loading of Rap1
proceeds through both Gi and Gq signalling by P2Y12
and P2Y1 receptors, respectively. The mechanism
initiated by the P2Y12 receptor is shown to be PI 3-
K-dependent while P2Y1-mediated activation of Rap1
requires Ca
2+ mobilisation (Woulfe et al. [93]; Greco
et al. [94]; Larson et al. [95]; Lova et al. [96, 97]).
Stimulation of the P2Y1 receptor also contributes to
platelet shape changes by a Ca
2+-independent path-
way. RhoA and its effector ROCK are activated by
ADP through G12/13 protein-dependent signalling of
the P2Y1 receptor and contribute to rapid actin
polymerization and shape changes (Paul et al. [98]).
Signalling towards Rho GTPases is also important in
other systems. In brain, ATP and ADP induce
membrane ruffling and chemotaxis of microglial cells
through Gi protein-dependent activation of Rac upon
stimulation of P2Y12/13 receptors (Sasaki et al. [51];
Honda et al. [54]). Stress fibre formation in vascular
smooth muscle cells is reported to be mediated by
RhoA/ROCK signalling that becomes activated upon
stimulation of P2Y1,P 2 Y 2, P2Y4 and P2Y6 receptors
(Sauzeau et al. [99]). In the latter study, information
concerning the signalling towards RhoA is lacking. In
a more recent study on endothelial cells, transactiva-
tion of VEGFR upon P2Y2 receptor stimulation and
recruitment of the RhoGEF Vav is shown to be a
possible mechanism to initiate RhoA-mediated cell
adhesion (Seye et al. [100]).
Although several P2Y receptors activate RhoA,
downstream signalling and physiological consequences
are determined by celltype specific mechanisms lead-
ing to diverse responses.
ERK signalling
Several GPCRs are coupled to enhanced proliferation
by multiple signal transduction pathways that phos-
phorylate ERK. Activation of this kinase requires Ras
or GTPases of the RhoA family and is often modulated
by second messenger-activated pathways, although
cross-talk with growth factor receptors also triggers
ERK signalling.
In neurons Gs protein-mediated activation of AC
increases ERK phosphorylation by a PKA/Rap1/B-
Raf cascade. In contrast, induction of cAMP synthesis
decreases ERK phosphorylation in C6 cells and
astrocytes by a negative action of PKA on the Ras/c-
Raf1 interaction, or by Rap1-mediated inhibition of c-
Raf1. These observations led to the hypothesis that an
increase in cAMP stimulates MEK/ERK signalling in
B-Raf expressing cells but inhibits this cascade in B-
Raf negative cells (Dugan et al. [101]). In both cases,
PKA activation has a central role and mediates its
effects through Src and Rap1 activation (Stork and
Schmitt [102]). Although the majority of cAMP-
dependent effects can be explained by this hypothesis,
a few exceptions are reported. In some B-Raf positive
cells, an increase in cAMP is shown to inhibit B-Raf,
suggesting that regulation of this kinase by cAMP also
depends on other cell type specific factors. One model
suggests the involvement of 14-3-3 proteins acting as
scaffolding proteins to shield B-Raf and Raf1 from
PKA phosphorylation (Qiu et al. [103]). Other studies
indicated that regulation of ERK by cAMP involves
multiple cell type specific mechanisms. In COS cells
overexpressing "-AR1 or "-AR2, stimulation of these
receptors activate AC through a Gs protein-dependent
mechanism as expected. However, PKA also phos-
phorylates these receptors and induces a switch from
Gs to Gi/o protein binding to "-AR resulting in
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et al. [104]). Modulation of the ERK cascade by cAMP
can also occur independently of PKA. In this context,
cAMP binds Epac1 or Epac2, Bexchange protein
directly activated by cAMP,’’ GEFs that activate
Rap1 and Rap2 (de Rooij et al. [105, 106]; Kawasaki
et al. [107]). Several examples of Gs protein-mediated
activation of ERK through Epac are reported
(Laroche-Joubert et al. [108]; Lin et al. [109]). Another
PKA-independent mechanism of ERK phosphoryla-
tion is the Gs"+/Src-mediated activation of Ras
(Schmitt and Stork [110]).
Gq and some Gi/o protein-coupled receptors activate
PLC" and trigger formation of IP3 and DAG, resulting
in Ca
2+ release and PKC activation, respectively. Ca
2+
increase can activate ERK through Pyk2 that activates
Ras as mentioned above. Otherwise, Ca
2+-dependent
modulation of Ras activity is also mediated by Ras
guanine nucleotide-releasing factor (RasGRF), a GEF
that contains Ca
2+- and DAG-binding domains,
(Ebinu et al. [111]) or by Ca
2+/calmodulin-dependent
kinases CaMK-II and CaMK-IV (reviewed in Agell
et al. [112]a n dW a l k e re ta l .[ 90]). Increase of
intracellular calcium and DAG formation also results
in activation of cPKCs while DAG formation alone is
sufficient to activate nPKCs. Increase in PKC activity
modulates the ERK cascade through Ras by inhibition
of RasGAPs and/or stimulation of RasGEFs. In
addition, PKC can activate Raf independently of Ras.
Indeed, it is shown that PKC! phosphorylates Raf at
Ser499 (Kolch et al. [113]). However, mutation of this
serine residue into alanine does not affect Raf activity
in response to phorbol esters (Yip-Schneider et al.
[114]). More convincing data were obtained when
constitutively active PKC was expressed in rat 6
fibroblasts. These cells display Ras-independent sig-
nalling towards ERK by direct phosphorylation of Raf
by PKC(. Since activation of Ras is required in several
systems this interaction is cell type-dependent (Cacace
et al. [115]; Ueffing et al. [116]). Direct phosphoryla-
tion of Raf by PKC is also involved in ERK activation
by the Gi protein-coupled leukotriene (LT)D4 receptor
in intestinal epithelial cells. Although stimulation of
this receptor also triggers a parallel PKC-independent
activation of Ras, transfection experiments confirmed
that Ras is dispensable for LTD4 receptor-mediated
ERK activation (Paruchuri et al. [117]). When consti-
tutive active point mutants of PKC!, PKC% and PKC(
were introduced in COS cells, only PKC% activated the
ERK cascade (Ueda et al. [118]), indicating that
involvement of PKC isoforms in ERK signalling vary
among different cell types. This is also confirmed by the
observation that, in platelets, cPKCs are involved in
thrombin-induced MEK and ERK activation indepen-
dently of Ras or Raf (Nadal-Wollbold et al. [119]).
Gi/o protein-coupled receptors that are not linked to
PLC activation can also modulate mitogenic signalling
through G"+-dependent activation of PI 3-K+. Signal-
ling from PI 3-K+ to ERK proceeds through Shc/Grb2/
SOS/Ras (Lopez-Ilasaca et al. [86]). An increasing
number of reports point to the involvement of PKCK in
Gi protein-dependent phosphorylation of ERK. The
first observation was made in CHO cells where
stimulation of the LPA receptor triggers MEK/ERK
signalling via a PI 3-K+-dependent activation of PKCK
not abrogated by transfection with dominant negative
Ras (Takeda et al. [120]). In addition, a recent report
indicated that angiotensin II-induced ERK activation
in rat vascular smooth muscle cells requires interaction
between Ras and PKCK (Zhao et al. [121]). PKCK-
dependent activation of ERK is mediated by inter-
action with MEK, a property shared by other PKC
isoforms (Scho ¨nwasser et al. [122]), or byregulation of
Raf1. Studies performed in rat embryonic hippocampal
cells indicated that PKCK can phosphorylate the Raf
kinase inhibitory protein (RKIP) resulting in dissocia-
tion of the Raf1/RKIP complex (Corbit et al. [123]). In
addition, co-immunoprecipitation experiments in COS
cells showed that modulation of c-Raf1 by PKCK is
also regulated by 14-3-3 scaffolding proteins (Van Der
Hoeven et al. [124]).
Initial studies concerning P2Y receptor-mediated
activation of ERK were made in astrocytes where this
cascade was shown to be involved in cell proliferation
and process elongation (Neary and Zhu [125]; King
et al. [126]).
Although ATP triggers pertussis toxin insensitive
IP3 and Ca
2+ responses in astrocytes, these are not
required for the signalling towards ERK which
depends on rapid membrane translocation of PKC%
upon phosphatidylcholine hydrolysis by PLD (Neary
et al. [73]). In PC12 cells, stimulation of the P2Y2 re-
ceptor also induces PKC%-dependent ERK phosphor-
ylation, although this mechanism requires Ca
2+ and
Pyk2 for the association of Shc and Grb2 to the
receptor and for subsequent activation of SOS/Ras/
Raf/MEK/ERK (Soltoff et al. [84]). Many reports
showed that P2Y receptor-mediated ERK signalling
requires PKC activation (Graham et al. [127]; Huwiler
and Pfeilschifter [128]; Erlinge [129]), but a PKC-
independent mechanism is reported in thyroid FRTL-
5 cells (Tornquist et al. [130]). In 1321N1 astrocytoma
cells, stimulation of the P2Y6 receptor with UDP acti-
vates PKC!, ( and K which are correlated with ERK
phosphorylation (Kim et al. [131]). Although the use of
general PKC inhibitors 3-[1-(dimethylaminopropyl)
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(GF109203X) and 12-(2-cyanoethyl)-6,7,12,13-tetrahy-
dro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-
carbazole (Go ¨ 6976) diminished ERK signalling, the
lack of specificity of these compounds makes it dif-
ficult to determine the contribution of each of these
PKC isoforms in the mechanism of ERK activation
(Way et al. [132]).
Enhanced proliferation by a P2Y receptor-mediated
stimulation of the ERK pathway has been reported in
a large number of cell types such as human mesangial
cells, vascular smooth muscle cells and primary astro-
cytes (Huwiler and Pfeilschifter [128]; Harper et al.
[133]). Transient ERK activation by P2Y1, P2Y2 or
P2Y12 receptor stimulation also increases cell prolifer-
ation in C6 cells indicating that activation of several
P2Y receptor subtypes can converge into the same
physiological response (Table 2) (Tu et al. [44]; Claes
et al. [39]; Czajkowski et al. [46]).
In addition to mitogenesis, P2Y receptor signalling
towards ERK elicits other physiological processes
including cell survival, inflammation and reactive
gliosis. In human lung microvascular endothelial cells,
hyperoxia-induced release of ATP results in cell
survival through ERK and PI 3-K signalling cascades
activated by P2Y2 and/or P2Y6 receptors, while
stimulation of the ERK cascade by the P2Y6 receptor
protects 1321N1 astrocytoma cells from TNF!-induced
apoptosis (Ahmad et al. [134]; Kim et al. [131]). Rapid
ERK1/2 and p38 MAPK activation plays an important
role in P2Y2 receptor-dependent primary granule
release from human neutrophils (Meshki et al. [135]).
A similar phenomenon is observed in articular chon-
drocytes where ATP acts as a pro-inflammatory medi-
ator by increasing arachidonic acid production and
release of prostaglandin E2 through a P2Y2 receptor-
dependent activation of p38 and ERK1/2 (Berenbaum
et al. [136]). In primary astrocytes, P2Y receptor-
mediated ERK activation by ATP is shown to induce
reactive astrogliosis, a phenomenon that occurs upon
brain injury and is characterised by astroglial prolifer-
ation, cellular hypertrophy and up regulation of GFAP.
This effect is mediated by an ERK-dependent increase
in the expression of COX-2 (Brambilla et al. [53]). In
C6 cells, P2Y12 and P2Y2 receptor-induced activation
of ERK is coupled to an enhanced cell proliferation,
while a negative modulation of GFAP synthesis by the
P2Y12 receptor is reported (Claes et al. [39]; Tu et al.
[44]; Van Kolen and Slegers [45]). These differences
are probably due to the fact that in C6 cells induction
of GFAP expression is not correlated with an en-
hanced proliferation but requires growth arrest.
In summary, most P2Y receptors are coupled to
ERK phosphorylation, but the signalling mechanism
and the physiological effect of this pathway are cell type
specific and are determined by the cellular context.
PI 3-K/PKB signalling
PKB/Akt is involved in a large variety of cellular
processes including glucose metabolism, mitogenesis,
differentiation, survival and motility (Brazil et al.
[137]). This member of the AGC protein kinase
superfamily is recruited to the plasmamembrane upon
PI 3-K-mediated PIP3 formation, but is also controlled
in a PI 3-K-independent, but calmodulin-dependent,
fashion upon intracellular Ca
2+ mobilisation by stimu-
lation of neuronal NMDA receptors (Cantley [138];
Leevers et al. [139]; Woodgett [140]; Yano et al. [141]).
Modulation of PKB activity is reported for a variety
of GPCR ligands including adrenergics, cannabinoids,
Table 2 G protein-dependent modulation of ERK and PKB signalling cascades in C6 cells.
G protein ERK PI 3-K/PKB Effect
P2Y1 Gq j PLC-PKC-Ca
2+-Ras. , Attenuation of PI 3-K
activated by growth
factors
Proliferation
P2Y2 Gq j PLC-PKC-Ca
2+-Ras. – Proliferation
P2Y12 Gi j RhoA-PKC-Raf-MEK j PI 3-K/PKB Proliferation/inhibition of
astrocytic differentiation
2OR Gi j FGF transactivation – Proliferation
"-AR Gs , Transient inhibition
dependent on cAMP
, Transient inhibition
by cAMP
Growth arrest/astrocytic
differentiation
CB Gs , Sustained inhibition , Sustained inhibition Growth arrest/apoptosis
Transient ERK activation by P2Y1 (Czajkowski et al. [46]), P2Y2
(Tu et al. [44]), P2Y12 (Grobben et al. [40]) and 2 opioid receptors
(2OR) (Belcheva et al. [198]) enhances cell proliferation while
stimulation of the "-adrenergic receptor ("-AR) transiently
inhibits ERK and PKB concomitant with induction of differenti-
ation (Wang et al. [149]; Van Kolen and Slegers [45]). Inhibition of
these pathways by cannabinoids (CB) is sustained and induces
apoptosis (Ellert- Miklaszewska et al. [184]).
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thrombin (Dickenson [142]; Franke et al. [143],
Iacovelli et al. [144] Murga et al. [145]; Sanchez et al.
[146]). Due to the existence of multiple phosphoinosi-
tide-dependent cascades, regulation of PKB signalling
by GPCRs varies among the studied systems.
In HEK293 cells, stimulation of "-AR with
(-)-isoproterenol activates PKB via Gs"+, Src, Ras and
PI 3-K (Schmitt and Stork [110]; Bommakanti et al.
[147]) while activation of AC by G!s exerts differential
effects on PKB activity. In cells expressing Epac, cAMP
activates PI 3-K/PKB via Rap1 while, in other cells,
cAMP activatesPKAthatexertsanegativeaction onPI
3-K and PKB (Mei et al. [148]; Wang et al. [149]).
Gi protein-mediated activation of PKB can occur
through the coupling of the G"+ subunit to the catalytic
subunit of PI 3-K or via growth factor receptor trans-
activation. Although only p110+ was initially reported
to be activated by G"+ subunits, this feature is also
observed for the p110" isoform (Kurosu et al. [150];
Stoyanov et al. [151]). This mechanism is reported in
Vero cells where stimulation with LPA activates Ras
upon increase in p110" lipid kinase activity (Yart
et al. [152]). Gi protein-mediated transactivation of
growth factor receptors is reported in HaCaT, A-431,
and HEK293 cells where stimulation of the angioten-
sin type I receptor by mechanical stress induces
transactivation of EGFR leading to activation of the
PI 3-K/PKB cascade and protection of these cells from
apoptosis (Kippenberger et al. [153]).
In 1321N1 astrocytoma cells, PLC" activation by the
Gq protein-coupled muscarinic M3 receptor also trig-
gers PI 3-K activation through ErbB3 transactivation,
but this mechanism requires Ca
2+ mobilisation (Tang
et al. [154]). In contrast, some reports showed an
inhibitory pathway from Gq protein-coupled receptors
towards PI 3-K by direct interaction between G!-
subunits released from heterotrimeric G proteins and
p110!, as reported for the !1A-AR in rat-1 fibroblasts
(Ballou et al. [155, 156]), or by inhibition of insulin
receptor substrate-1-associated PI 3-K activity in
1321N1 astrocytoma cells by carbachol, histamine or
thrombin. These observations reveal opposing effects
of muscarinic receptor stimulation on PI 3-K activity
mediated by insulin and ErbB3 receptors in these cells
(Batty et al. [157]).
Modulation of PI 3-K/PKB signalling is also reported
for a few P2Y receptors. In bovine adventitial fibro-
blasts, ATP is shown to induce proliferation through
parallel but independent ERK and PI 3-K signalling
cascades that contribute to mTOR and p70S6K phos-
phorylation (Gerasimovskaya et al. [158]). In rat
mesangial cells, stimulation of the P2Y2 receptor with
ATP or UTP activates PKB by a PDK-1-dependent
mechanism while, in C6 cells, ADP activates PI 3-K/
PKB by the Gi protein-coupled P2Y12 receptor but
inhibits PI 3-K by stimulation of the Gq/G11/12 protein-
coupled P2Y1 receptor (Table 2) (Van Kolen and
Slegers [45]; Czajkowski et al. [46]; Huwiler et al.
[159]). Although most effects of P2Y-mediated activa-
tion of PI 3-K signalling are known to be related to cell
proliferation, differentiation and survival, this signal-
ling cascade is also involved in other processes. In this
regard, it can be mentioned that P2Y12 receptor-
mediated PI 3-K/PKB activation modulates prolifera-
tion and differentiation of C6 cells, but also plays an
important role in ADP-induced platelet aggregation
(Van Kolen and Slegers [45]; Czajkowski et al. [46];
Chen et al. [160]; Kim et al. [161]).
P2Y receptor-integrated G protein-coupled receptor
and receptor tyrosine kinase signalling cascades
G protein-coupled receptor cross-talk
Complementary to vertical downstream signalling upon
GPCR stimulation, these receptors also mediate lateral
signalling by cross-talk with other receptors (reviewed in
Cordeaux and Hill [162]). In human platelets, it was
reported that P2Y12 receptor activation potentiates
P2Y1 receptor-mediated Ca
2+ signalling, while the
P2Y1 receptor negatively regulates this action (Hardy
et al. [163]). In renal mesangial cells, P2Y receptors
activated by ATP and UTP induce a rapid desensitisa-
tion of the sphingosine-1-phosphate (S1P) receptor by
PKC-dependent phosphorylation (Xin et al. [164]). A
more complex interplay is observed between P2Y
receptors and 5-HT receptor subtypes. Studies per-
formed in CHO cells stably expressing 5-HT1A recep-
tors revealed that the responsiveness of this receptor is
reduced by a PLD/PKC-dependent phosphorylation
upon short (<5 min) pre-treatment with ATP, while
the agonist efficacy of the overexpressed 5-HT1B
receptor is not altered. Alternatively, longer treatment
with ATP alone attenuates 5-HT1B signalling by a
mechanism that requires activation of phospholipase
A2 (PLA2) (Berg et al. [165]). Furthermore, stimulation
of P2Y receptors can also modulate the release of
transmitter molecules, including dopamine, glutamate
and serotonin (Bezzi and Voltera [52]; Krugel et al.
[166]; Nedergaard et al. [167]). A recently discovered
mechanism of GPCR cross-talk is the assembly of a
heteromeric receptor complex displaying the pharmaco-
logical profile of one receptor and the signalling proper-
ties of the other. Such an interaction is reported in
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The heteromeric A1-P2Y1 receptor complex inhibits
AC through Gi/o protein, but displays P2Y1 receptor-
like pharmacological properties (Yoshioka etal. [168]).
P2Y receptor-mediated transactivation
Many studies reveal that GPCRs and growth factor
receptors share a number of signalling modules
(e.g., Raf/MEK/ERK, PI 3-K/PDK/PKB) to transduce
their effects. In the past decade, it has become clear
that the signalling pathways of both receptor systems
are interconnected. Stimulation of a GPCR can induce
a rapid tyrosine phosphorylation of RTKs. This trans-
activation mechanism is reported for many GPCRs
and proceeds through the G"+ subunit-dependent
activation of Src. Src in turn activates RTKs by
phosphorylation of specific tyrosines located in their
intracellular domains or induction of matrix metal-
loproteases-dependent release of growth factor recep-
tor ligands, e.g., release of heparin-bound EGF
(Luttrell and Luttrell [169]).
Another target for signal integration of GPCRs and
RTKs are docking proteins. Although these proteins
contain phospho-tyrosine binding domains that inter-
act with phosphorylated tyrosine residues of RTKs,
stimulation of GPCRs can induce growth factor
receptor-independent phosphorylation of docking pro-
teins by Src (Bisotto and Fixman [170]).
In addition to GPCR-dependent phosphorylation of
RTKs, the opposite activation mechanism is also
reported. Binding of PDGF to its cognate receptor
induces association of PDGFR with the Gi protein-
coupled S1P receptor. Subsequently, Src is recruited to
this complex by G"+ subunits and phosphorylates
Grb-2 associated binder-1 resulting in dynamin
II-induced Bpinching off’’ of vesicles involved in
endocytosis of PDGF-S1P signalling complexes and
subsequent activation of ERK1/2 (Waters et al. [171]).
Cross-talk between RTKs and P2Y receptors is
reported in Mu ¨ller glial cells where ATP exerts its
mitogenic effect through transactivation of EGF and
PDGF receptors resulting in ERK-dependent en-
hanced proliferation. In these cells, ATP-induced
activation of ERK was abolished by treatment with
the RTK autophosphorylation inhibitor tyrphostin
(AG1478) (Milenkovic et al. [172]). In rat striatal
astrocytes, ATP and bFGF activate ERK and induce
astrogliosis by a mechanism that is insensitive to
RTK inhibition (Abbracchio et al. [173]; Bolego et al.
[174]; Neary et al. [175]). More recently, mechanistic
studies performed in 1321N1 astrocytoma cells reveal
that the human P2Y2 receptor interacts with Src and
Pyk2, probably by its proline-rich putative SH3
binding sites (PXXP). This interaction is implicated
in P2Y2 receptor-induced transactivation of EGF,
PDGF and VEGF receptors (Liu et al. [176]; Seye
et al. [100]). Src inhibition abolishes growth factor
receptor transactivation and ERK phosphorylation.
Although the rat P2Y2 receptor lacks PXXP motives,
tyrosine kinase-dependent activation of ERK upon
P2Y2 receptor stimulation is reported in a few rat cell
lines, including C6 and PC12 cells (Soltoff et al. [84];
Tu et al. [44]). In the latter cases, P2Y2 receptor-
dependent activation of Pyk2 is mediated by PKC and
Ca
2+ suggesting that the PXXP sequence is dispens-
able for P2Y2 receptor-induced tyrosine phosphoryla-
tion of Pyk2 and downstream signalling towards ERK.
Moreover, P2Y2 mutants lacking PXXP-motives are
still able to activate ERK demonstrating the existence
of other pathways towards phosphorylation of ERK
(Liu et al. [176]). Observations made in human
endothelial cells, where UTP-induced signalling to
ERK was shown to depend on Ca
2+,P K Ca n d
integrin-mediated cell anchorage, already pointed to
a pathway distinct from the classical Ras/Raf/MEK/
ERK cascade (Short et al. [177]). Human and mouse
P2Y2 receptors contain a RGD sequence which allows
activation of ERK by interaction with !V"3/"5 integrins
followed by Go protein coupling. Since these proteins
also mediate cell adhesion and chemotaxis, the ob-
served P2Y2/!V"3/"5-interaction also points to a possi-
ble function of P2Y2 receptors in inflammatory
responses (Erb et al. [178]).
It is clear that, in analogy with other GPCRs, cross-
talk between P2Y and growth factor receptors may
occur at different levels of the signal transduction
pathway depending on receptor subtypes and on the
studied system. For the P2Y2 receptor, additional
transactivation mechanisms are facilitated by the
presence of signalling motives (e.g., PXXP or RGD)
that allow direct interaction with other signalling
components (Src, integrins).
P2Y receptor-activated signal transduction pathways
in C6 glioma cells
As mentioned above, the final outcome of nucleotide-
mediated signalling is influenced by ecto-enzymes
(Claes and Slegers [17]; Czajkowski and Baranska
[18]; Grobben et al. [21, 179]). ATP and ADP hy-
drolysis to adenosine results in growth inhibition by a
mechanism that is not yet fully understood. When
nucleotide hydrolysis is prevented, ATP, ADP and
ApnA (in particular Ap3A and Ap4A) increase cell
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2MeSADP, a P2Y agonist not hydrolysed by the
ecto-enzymes present on the plasma membrane of C6
cells, also results in growth enhancement and inhibi-
tion of "-AR-induced differentiation into astrocyte
type II (Claes et al. [39]; Van Kolen and Slegers [45]).
The pathways involved in the P2Y receptor-dependent
effects on growth and differentiation of these cells are
presented in Figure 1.
Nucleotides stimulate several purinergic receptors
that activate the ERK cascade by at least two distinct
mechanisms. The P2Y2 receptor, stimulated by UTP
and ATP, enhances ERK phosphorylation through a
PLC"/PKC/Ras/Raf/MEK cascade that is attenuated
by inhibition of tyrosine kinases and Ca
2+ chelation by
BAPTA-AM (Tu et al. [44]). The Ca
2+-dependence of
the P2Y2 receptor-mediated activation of ERK sug-
gests the involvement of a cPKC (!, "I, "II or +). It is
also shown that ADP stimulates the P2Y1 receptor and
activates ERK through a Ca
2+-dependent mechanism
(Czajkowski et al. [46]), likely by a similar mechanism
as reported for the P2Y2 receptor (Tu et al. [44]). In
addition, it has been shown that ADP can activate
ERK by stimulation of the P2Y12 receptor through a
RhoA- and PKC-dependent pathway that does not
require Ca
2+, Ras or tyrosine kinase activation
(Grobben et al. [40]). The fact that Ca
2+ removal does
not affect P2Y12 receptor-mediated ERK activation
excludes the involvement of cPKCs. Stimulation of the
P2Y12 receptor does not induce PI-turnover, but
nPKCs might be involved since alternative activation
mechanisms, based on Ser/Thr and Tyr phosphoryla-
tion, have been reported (Steinberg [180]; Parekh et al.
[181]). Data from our laboratory suggest an important
role for PKCK in P2Y12 receptor-dependent activation
of ERK. The fact that no cross-talk between ERK and
PI 3-K is observed in C6 cells indicates that PKCK
exerts its actions independently of PI 3-K via a RhoA-
Figure 1 Overview of P2Y receptor-mediated signalling cascades in C6 cells. Green and red lines represent stimulatory (green arrows)
and inhibitory (red squares) actions respectively. Dashed lines are incomplete characterised pathways. P2Y2 receptor stimulation
enhances ERK-dependent proliferation through a PLC-dependent pathway while P2Y12 receptor stimulation enhances cell
proliferation by RhoA- and PKCK-dependent activation of ERK (Claes et al. [39]; Grobben et al. [40]; Tu et al. [44]; Van Kolen
and Slegers, unpublished data). P2Y12 receptor stimulation also inhibits cAMP-dependent induction of differentiation by reactivation
of PKB which requires Src/Pyk2 complex formation and Rap1 activation. Formation of the Src/Pyk2 complex requires Ca
2+ and PLD2
which is constitutively active (Claes et al. [22]; Van Kolen and Slegers [45]; Van Kolen et al. [185]). Cyclic AMP-dependent inhibition
of PKB and ERK is suggested to depend on inhibition of Rap1 (Wang et al. [149]). The negative modulation of PI 3-K by the P2Y1
Figure 1 Overview of P2Y receptor-mediated signalling cascades
in C6 cells. Green and red lines represent stimulatory (green
arrows) and inhibitory (red squares) actions respectively. Dashed
lines are incomplete characterised pathways. P2Y2 receptor
stimulation enhances ERK-dependent proliferation through a
PLC-dependent pathway while P2Y12 receptor stimulation
enhances cell proliferation by RhoA- and PKCK-dependent
activation of ERK (Claes et al. [39]; Grobben et al. [40]; Tu
et al. [44]; Van Kolen and Slegers, [199]). P2Y12 receptor stimu-
lation also inhibits cAMP-dependent induction of differentia-
tion by reactivation of PKB which requires Src/Pyk2 complex
formation and Rap1 activation. Formation of the Src/Pyk2
complex requires Ca
2+ and PLD2 which is constitutively active
(Claes et al. [22]; Van Kolen and Slegers [45]; Van Kolen et al.
[185]). Cyclic AMP-dependent inhibition of PKB and ERK is
suggested to depend on inhibition of Rap1 (Wang et al. [149]).
The negative modulation of PI 3-K by the P2Y1 receptor is only
displayed in the presence of serum (Czajkowski et al. [46])
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and Slegers, [199]). Although P2Y receptors use
different mechanisms to activate ERK, they all con-
verge to increased cell proliferation by enhanced
synthesis of c-Myc, c-Jun and c-Fos (Zhang et al.
[182]). Progression through the G1/S phase of the cell
cycle is due to a decreased expression of p27
Kip and
increased expression of cyclinD.
While stimulation of ERK signalling by P2Y recep-
tors has been known for several years, the coupling with
PI 3-K activation was discovered more recently. When
C6 cells are grown in the presence of serum, P2Y1
receptor signalling predominates and is shown to
inhibit PI 3-K (Czajkowski et al. [46]). Upon serum
deprivation, P2Y1 receptor expression decreases while
P2Y12 becomes the main ADP-stimulated receptor
that enhances the activity of PI 3-K by a Gi protein-
dependent mechanism. These observations demon-
strate that, in addition to autocrine growth factor
receptor signalling, the constitutive PI 3-K activity in
C6 cells is modulated by P2Y1 and P2Y12 receptor
expression. Another cross-talk at the level of PI 3-K/
PKB is observed for P2Y12 and "-AR. Increase in
cAMP upon stimulation of the latter receptor tran-
siently inhibits PKB phosphorylation. Stimulation of
the P2Y12 receptor, which negatively affects AC, does
not only counteract this inhibition but even enhances
PKB activity in comparison to unstimulated cells,
suggesting that P2Y12 receptor-mediated PI 3-K/PKB
activation is not only due to its inhibitory effect on AC
(Van Kolen and Slegers [45]; Czajkowski et al. [46];
Baranska et al. [183]). In addition to their opposing
effects on PI 3-K/PKB signalling, unpublished data of
our laboratory revealed similar modulation of ERK
signalling by P2Y12 and "-AR. Whether the P2Y12
receptor-mediated reversal of ERK inhibition is in-
volved in the inhibition of "-AR-induced GFAP
synthesis remains to be determined. The observation
that stimulation of the cells with UTP activates ERK,
but fails to inhibit the "-AR-induced growth arrest and
GFAP synthesis, suggests that ERK activation alone is
not sufficient to counteract differentiation (Claes et al.
[39]; Tu et al. [44]). Conversely, transfection of C6 cells
with constutively active PKB prevented (-)-isoproter-
enol-induced differentiation indicating that inhibition
of PKB signalling is required for cAMP-dependent
induction of differentiation. Apparently this observa-
tion is in contrast with data showing that cAMP-
dependent induction of differentiation requires PI 3-K
activity which is not inhibited upon a 48-h treatment
with dbcAMP (Roymans et al. [34]). This might be
explained by the fact that induction of differentiation
by stimulation of "-AR proceeds through transient
inhibition of PKB while recovery of this activity is
required to prohibit cell death. This hypothesis is
confirmed by a recent study where sustained inhibition
of PI 3-K/PKB by cannabinoids is shown to induce
apoptosis in C6 cells (Table 2) (Ellert-Miklaszewska
et al. [184]). Taken together, P2Y12 receptor stimula-
tion inhibits cAMP-dependent induction of differenti-
ation by a transient increase in PI 3-K/PKB activity.
Ca
2+ chelation inhibits the basal PKB activity and
P2Y12 receptor-mediatedincreaseinPKBphosphoryla-
tion. Although C6 cells also express the P2Y2 receptor,
stimulation with UTP does not enhance the activity of
PI 3-K/PKB, which may be explained by a differential
coupling to G protein subtypes. P2Y2 receptor-mediat-
ed signalling proceeds through Gq proteins while the
activation of PDK is Gi protein-dependent (Table 2)
(Tu et al. [44]; Huwiler et al. [159]). The lack of Gi
protein coupling of the P2Y2 receptor in C6 cells might
be a consequence of compartimentalisation into cav-
eolae as reported for some Gq protein-coupled recep-
tors (Bhatnagar et al. [81]).
Althoughexperimentsin CHO cells revealthatP2Y12
receptor-induced ERK activation requires PI 3-K+
( S o u l e te ta l .[ 92]), experiments performed with
LY294002 or Wortmannin excluded cross-talk between
both cascades in C6 cells (Grobben et al. [40]). These
differences in signalling mechanisms can be explained
by the fact that the latter PI 3-K-isoform is only
moderately expressed in C6 cells (Van Kolen and
Slegers [45]). The exact mechanism of P2Y12 receptor-
induced PI 3-K/PKB activation is not fully understood,
but recent data revealed that Src and Pyk2 are involved
in P2Y12 receptor signalling to PI 3-K (Van Kolen et al.,
[185]). A similar pathway is observed in PC12 cells
where Src, in complex with Pyk2 and PLD2, activates
PI 3-K in response to H2O2 (Banno et al., [186]). Since
PLD2 is constitutively active in C6 cells (Bobeszko
et al. [187]), a significant role for this enzyme in PI 3-K/
Akt signalling is suggested. Although Soulet et al. [92]
reported that transactivation of PDGFR is involved in
PI 3-K activation by the P2Y12 receptor in CHO cells,
the use of receptor kinase inhibitors indicated that
PDGFR and EGFR are not transactivated by the P2Y12
receptor in C6 cells. Alternatively, a Rap1-mediated
activation of PI 3-K by the P2Y12 receptor cannot be
excluded. Indeed, PI 3-K is postulated as a downstream
effector of Rap1 that is inhibited by an increase in
cAMP concentration (Wang et al. [149]). Data from our
laboratory indicated a rapid P2Y12 receptor-induced
activation of Rap1 that was abolished by Ca
2+ chelation
and inhibition of Src/Pyk2 complex formation but not
by PI 3-K inhibition (Van Kolen et al. [185]). These
results positioned Rap1 downstream of Src/Pyk2 but
462 Purinergic Signalling (2006) 2:451–469upstream of PI 3-K. In addition, this mechanism
involves G"+ protein subunits and Ca
2+-dependent
activation of Pyk2 that requires association to IGF-IR
and PLD2 to interact with Src. Although Src and Pyk2
are shown to activate Ras/Raf/MEK/ERK in primary
astrocytes (Wang and Reiser [83]), this mechanism did
not contribute to P2Y12 receptor-mediated ERK acti-
vation in C6 cells pointing to a physical separation of
both cascades (Grobben et al. [40]; Van Kolen and
Slegers, [199]). Indeed, the formation of a Pyk2/Src/
PLD2/IGFI-R complex may contribute to compartmen-
talisation of this signalling pathway that requires intact
lipid rafts to be active (Van Kolen et al. [185]). In
contrast, in blood platelets Rap1, but also Pyk2
activation by the P2Y12 receptor, depends on PI 3-K
activity but is insensitive to Ca
2+ chelation (Lova et
al. [96, 97]; Koziak et al. [188]). These findings indicate
that different cell specific pathways are involved in
P2Y12 receptor-mediated activation of PI 3-K/PKB and
additional research is required to allow full character-
isation of these signalling cascades.
Conclusions
At present, nucleotides are known to regulate a variety
of biological processes related to vascular-, immuno-
logical- and intestinal functioning. In vitro studies on
glial and neuronal cells implicated the P2Y receptor-
activated signalling pathways in regulation of cell
motility, proliferation, chemotaxis and protection
against oxidative stress. Furthermore, investigations
on tumoral cells demonstrated that stimulation of P2Y
receptors contribute to tumorigenesis by increasing
cell proliferation through ERK and PKB signalling
pathways activated by independent mechanisms. From
these observations, a role of these receptors as
potential targets in clinical applications emerges.
P2Y receptors modulate these physiological func-
tions by activation of GTPases and direct or indirect
activation of protein kinases. Characterisation of the
involved receptor(s) and elucidation of P2Y receptor-
induced activation of defined pathways needs to be
improved by synthesis of specific P2Y agonists and
antagonists.
Studies on P2Y receptor-mediated signalling, dis-
cussed in this review, demonstrate that besides vertical
signal transduction, lateral cross-talk between growth
factor receptors and GPCRs extends the signalling
properties of a defined receptor subset. It also becomes
clear that signal transduction pathways activated by
P2Y receptors largely depend on the cell type and their
environment. On the one hand, cellular specificity is
determined by differential expression of signalling
proteins, but on the other hand also depends on the
assembly of signalling modules. Besides specific pro-
tein-protein interactions, intracellular compartmentali-
sation (e.g., lipid rafts, clathrin-coated vesicles) also
contributes to the specificity of receptor signalling.
Identification of the signalling modules and cellular
compartmentalisation will provide more insight into the
P2Y receptor-activated signalling cascades.
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